NYSE · MISCELLANEOUS FOOD PREPARATIONS & KINDRED PRODUCTS · MID CAP
Medifast, Inc. MED
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$385.8M
▼ 36.0% vs FY2024
EPS · FY25
$-1.70
Dividend / sh · FY25
$0.00
Payout · FY25
-1%
ROE · FY25
-9.1%
Net margin · FY25
-4.8%
Dividend coverage
1.8×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 385.8M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 5 cents on every revenue dollar this year.
Per share
USD -1.70
Diluted EPS, FY2025
EPS
Dividend
Earnings covered the dividend 1.8 times — the rest stayed in the company.
Profitability
-9.1%
Return on equity, FY2025
ROE
Operating margin-3.7%
Net margin-4.8%
Return on assets-7.0%
Each USD of equity lost 9 cents this year.
Returned to shareholders
USD 195,000.00
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 195,000.00
Net buybacksUSD 0.00
Share of profit-1.0%
Consecutive raises—
USD 195,000.00 in dividends went back to shareholders in a year without profit.
Growth
−16.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−37.7%
−16.2%
+3.5%
+2.7%
Returned to shareholders
−90.1%
−67.8%
−32.9%
+12.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years−6.6%
Change, 10 years−6.8%
The share count shrank 7% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 248.0M
total assets, end of FY2025
Total assetsUSD 248.0M
EquityUSD 198.9M
CashUSD 89.3M
Current ratio4.69×
Equity funds 80% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.4
0.6
1.1
1.6
1.5
0.9
0.7
0.5
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.2
Operating income $B
−0.0
0.0
0.1
0.2
0.2
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
EBITDA $B
0.0
0.0
0.1
0.2
0.2
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Income tax $B
0.0
0.0
0.0
0.0
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
0.0
0.1
0.1
0.2
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
EPS, diluted $
−1.70
0.19
9.10
12.73
13.89
8.68
6.43
4.62
2.29
1.49
1.66
1.03
1.73
1.16
1.31
1.35
0.77
Dividend / sh $
0.00
0.00
4.95
6.56
5.68
4.52
3.38
2.19
1.44
1.07
0.25
0.00
0.00
·
·
·
·
Payout %
−1
34
73
50
39
52
45
42
56
67
·
·
·
·
·
·
·
ROE %
−9.1
1.0
55.8
80.3
91.2
78.5
72.8
51.7
27.4
19.3
23.7
14.7
25.3
19.3
25.5
32.7
23.8
Shares out B
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.02
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
66 of 66
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed